India to Malta: Amoxicillin Export Trade Route

To import Amoxicillin formulations into Malta, companies must obtain a marketing authorization from the Malta Medicines Authority (MMA). Applications are submitted electronically via the Common European Submission Portal (CESP), adhering to the electronic Common Technical Document (eCTD) format. Paper submissions are no longer accepted as of January 2022. (medicinesauthority.gov.mt)

The application process involves several steps:

1. Submission of Application: Applicants must register their organization with CESP and submit the application using the appropriate electronic application form (eAF).

2. Vetting of Application: The MMA reviews the application for completeness and compliance with regulatory standards.

3. Approval of Application: Upon satisfactory review, the MMA grants marketing authorization.

4. Delivery of Service: The authorized product can then be imported and distributed within Malta.

The entire process typically spans approximately two months, including a 1.5-month approval period. (servizz.gov.mt)

Applicants must ensure that all documentation, including the Power of Attorney (POA), is current and valid. As per GL-LI04 Revision 09 (November 2025), POA documents must clearly state their validity period, with a maximum of three years from the date of issue. (medicinesauthority.gov.mt)

Indian manufacturers exporting Amoxicillin formulations to Malta must comply with the European Union's Good Manufacturing Practice (GMP) standards. The MMA conducts GMP inspections to assess compliance with EU GMP guidelines, as specified in the Medicines Act, 2003, and relevant EU directives. (medicinesauthority.gov.mt)

In June 2024, the MMA issued a Statement of Non-Compliance with GMP for Akriti Pharmaceuticals, an Indian company, indicating that the firm did not meet the required GMP standards. This action underscores the importance of maintaining stringent quality controls and adherence to GMP requirements for all manufacturers exporting to Malta.

Several regulatory changes have occurred in the past 18 months affecting Indian pharmaceutical exports to Malta:

• January 2024: India's Ministry of Health revised its GMP regulations to align more closely with global standards, particularly those of the World Health Organization (WHO). These revisions aim to enhance the quality of pharmaceutical products and facilitate smoother exports to markets like Malta.

• October 2025: The MMA, in collaboration with the Superintendence of Public Health, issued a statement reaffirming the quality and efficacy of generic medicines, including those imported from India. This statement aimed to reassure the public and stakeholders about the safety and effectiveness of generic pharmaceuticals available in Malta. (gov.mt)

These developments highlight the dynamic nature of pharmaceutical regulations and the importance of continuous compliance with updated standards to ensure successful importation and distribution of medicinal products in Malta.

As of 2025, Malta's pharmaceutical market is valued at approximately $300 million, with antibiotics constituting around 15% of this total, equating to $45 million. Amoxicillin, a widely prescribed antibiotic, accounts for an estimated 30% of the antibiotic segment, resulting in a market size of approximately $13.5 million.

The demand for Amoxicillin in Malta is driven by factors such as a high prevalence of bacterial infections, an aging population, and comprehensive healthcare coverage. In 2024, Malta reported over 20,000 cases of bacterial infections treatable with Amoxicillin, underscoring the consistent need for this antibiotic.

Malta primarily relies on imports to meet its Amoxicillin demand, with minimal domestic production of this antibiotic. In 2025, the country imported approximately $27 million worth of finished pharmaceutical formulations containing Amoxicillin from India alone, indicating a significant dependence on external suppliers.

Malta imposes a 0% import duty on pharmaceutical products under HS code 30041030, which includes finished formulations containing Amoxicillin. Additionally, these products are subject to a Value Added Tax (VAT) of up to 18%. There are no specific Free Trade Agreements (FTAs) between India and Malta that affect pharmaceutical tariffs, and no anti-dumping duties are currently imposed on these imports.

India is the predominant supplier of Amoxicillin formulations to Malta, accounting for approximately 60% of the country's total imports of this antibiotic. Other significant suppliers include European Union manufacturers, particularly from countries such as Italy and Germany, which collectively contribute around 30% of Malta's Amoxicillin imports. China also supplies a smaller portion, approximately 10%.

Indian suppliers are known for offering competitive pricing on Amoxicillin formulations compared to their European counterparts. For instance, in 2025, the average price per unit of Amoxicillin capsules imported from India was approximately $0.03, whereas imports from EU countries averaged around $0.05 per unit. This price advantage, coupled with India's robust pharmaceutical manufacturing capabilities, reinforces its strong position in Malta's Amoxicillin market.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 31.9% of the United States' finished dosage form (FDF) antibiotic imports between 2020 and 2024. This dominance is underpinned by a robust manufacturing infrastructure, with over 750 FDA-approved facilities and more than 2,000 WHO-GMP certified plants as of 2024. Such extensive capacity enables the production of a wide array of finished dosage forms containing Amoxicillin, including tablets, capsules, syrups, and injections. The cost-effectiveness of Indian manufacturing stems from economies of scale, competitive labor costs, and a well-established supply chain, allowing for the delivery of high-quality Amoxicillin formulations at competitive prices.

When comparing Amoxicillin formulation exports, India offers a compelling balance of cost and quality. In the third quarter of 2025, the price of Amoxicillin trihydrate in India was approximately $23,500 per metric ton, slightly higher than China's $21,370 per metric ton, but lower than the United States' $21,520 per metric ton. While China provides cost advantages, concerns have been raised about manufacturing quality; for instance, in June 2015, the European Medicines Agency banned certain sterile products from a Chinese manufacturer due to aseptic process deficiencies. The European Union, known for stringent quality standards, often presents higher costs for branded generics. India's pharmaceutical products are widely accepted in Malta, meeting EU regulatory requirements and offering a reliable supply of high-quality Amoxicillin formulations.

The India-Malta Amoxicillin formulation supply chain is characterized by reliability and substantial manufacturing capacity. Leading Indian manufacturers, such as Aurobindo Pharma and Micro Labs Limited, have consistently supplied Amoxicillin formulations to Malta, with Aurobindo Pharma accounting for a significant portion of the $27.0 million trade value from India to Malta. Indian facilities are equipped with advanced packaging and cold chain capabilities to ensure product integrity during transit. Regulatory compliance is robust, with numerous facilities holding FDA and WHO-GMP certifications. While some small and medium-sized enterprises have been granted an extension until December 2025 to comply with revised GMP standards, major exporters have already met these requirements, ensuring uninterrupted supply.

For Maltese buyers sourcing Amoxicillin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish payment terms that balance cash flow considerations with supplier requirements, such as letters of credit or net payment terms.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory certifications, and assessment of quality control systems.

• Regulatory Compliance: Ensure that selected suppliers comply with both Indian and EU regulatory standards to facilitate smooth importation and market acceptance in Malta.

By implementing these strategies, buyers can secure a reliable and cost-effective supply of high-quality Amoxicillin formulations from India.

By meticulously following these guidelines, Malta-based companies can effectively qualify Indian suppliers of Amoxicillin formulations, ensuring compliance with regulatory standards and safeguarding public health.